Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 77Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adoptive Transfer × 1 year × Clear all
NCT05639972 2026-02-27

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Rutgers, The State University of New Jersey

Phase 1/2 Recruiting
15 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡